Therapeutic drug monitoring (TDM) plays a significant role in achieving the best patient outcomes and delivering cost-effective treatments. Many factors affect drug metabolism – including variations between individuals, changes over time and drug-on-drug interactions.
Continuous and automated real-time online monitoring (CAR-TOM) of therapeutic drugs using Probe Scientific’s MicroEye® technology helps clinicians optimise the dose and maintain blood drug levels within the therapeutic window.
Benefits of real-time TDM
- Ensuring the drug dose is sufficient to achieve therapeutic effect.
- Reduction in toxic or other unwanted side-effects.
- Improved clinical outcomes.
- Shorter hospital stays and lower healthcare costs.
Probe’s NanoDem project aims to set new standards in the care of transplant patients by developing a novel therapeutic drug monitoring device for point-of-care measurement of immunosuppressants in transplanted patients, based on the MicroEye®.
The latest exciting news is that German partners at the Klinikum rechts der Isar der Technischen University in Munich have identified a new method to enhance the system’s sensitivity, as the focus is on measuring the important pharmacologically active fraction of the drugs administered rather than, as is current practice, determining total levels and then making assumptions on how well the drug is working.
The NanoDem project uses Probe’s innovative MicroEye® device allied to analytical systems being developed by the other consortium partners: the Italian National Research Council, University of Tübingen, Datamed Srl, Universidad Complutense de Madrid, University of Stuttgart, INESC Microsistemas e Nanotecnologias, and Microfluidic ChipShop GmbH. The project is an EU FP7 initiative with a budget of approximately €5 million.
Continuous monitoring of drugs and immunosuppressants